NEW YORK, Feb. 23, 2015 /PRNewswire/ --
www.FinancialBuzz.com, a leader in the digital financial news
space, video production and integration of social media, today
announces an exclusive HD video interview with CEL-SCI Corp. (NYSE
MKT: CVM) Chief Executive Officer, Geert
Kersten from the floor of the New York Stock Exchange
(NYSE).
Mr. Kersten provides the latest insight and why he is very
excited about CEL-SCI's future and touches on multiple potential
catalyst events coming up in 2015. Why is Mr. Kersten so bullish?
Have insiders increased their positions? What is currently
happening with the company's lead investigational therapy Multikine
(Leukocyte Interleukin, Injection) study in a pivotal Phase III
clinical trial against head and neck cancer?
Hear it first and directly from the CEO of CEL-SCI Corp. Just
two months into 2015, shares of CEL-SCI Corporation (NYSE MKT: CVM)
have surged as high as 83% (based on January
2, 2015 low of $.59 and
February 19, 2015 high of
$1.08).
Click here to view full HD quality video interview
https://www.youtube.com/watch?v=FoLpbuZnZEM
About Financial Buzz Media
FinancialBuzz.com, a leading informational web portal designed
to provide the latest trends in Market News, Investing News,
Personal Finance, Politics, Entertainment, in-depth broadcasts on
Stock News, Market Analysis and Company Interviews. A pioneer in
the financially driven digital space, video production and
integration of social media, FinancialBuzz.com creates 100% unique
original content.
Financial Buzz Media provides credible branding, marketing and
advertising through our unique media platform that includes
Newswire Delivery, Digital Advertising, Social Media Relations, TV
Broadcasting, and Financial Publications. In a public financial
market that requires extensive transparency and disclosures,
Financial Buzz Media provides one of the most internationally
credible media outlets by reporting live from various locations;
The New York Stock Exchange, NASDAQ Exchange and Hong Kong
Exchange.
For "the latest buzz in financial news" every day, please visit
www.FinancialBuzz.com.
About CEL-SCI Corporation
CEL-SCI's work is focused on finding the best way to activate
the immune system to fight cancer and infectious diseases. CEL-SCI
believes that the best way may be to activate the immune system of
patients before they have received surgery, radiation and/or
chemotherapy. Its lead investigational therapy Multikine (Leukocyte
Interleukin, Injection) is currently being studied in a pivotal
Phase III clinical trial against head and neck cancer. If the study
endpoint, which is a 10% improvement in overall survival of the
subjects treated with Multikine treatment regimen as compared to
subjects treated with current standard of care only is satisfied,
the study results will be used to support applications which will
be submitted to regulatory agencies in order to receive from these
agencies commercial marketing approvals for Multikine in major
markets around the world. Additional clinical indications for
Multikine which are being investigated include cervical dysplasia
in HIV/HPV co-infected women, and the treatment of peri-anal warts
in HIV/HPV co-infected men and women. A Phase I trial of the former
indication has been completed at the University of Maryland. The latter indication is
now in a Phase I trial in conjunction with the U.S. Navy under a
CRADA.
CEL-SCI is also developing its LEAPS technology for the
treatment of pandemic influenza and as a potential therapeutic
vaccine against rheumatoid arthritis. CEL-SCI received a Phase I
SBIR Grant from the National Institutes of Health to develop LEAPS
as a potential treatment for rheumatoid arthritis with researchers
from Rush University Medical Center in
Chicago, Illinois. The Company has
operations in Vienna, Virginia,
and in/near Baltimore,
Maryland.
For more information, please visit www.cel-sci.com.
Media Contact:
Henry Wong, +1-(877)-601-1879 or
Henry@financialbuzz.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/financialbuzzcom-exclusive-interview-with-cel-sci-ceo-geert-kersten-from-the-floor-of-the-nyse-300039567.html
SOURCE Financial Buzz Media